Skip to content

Randomized controlled trial of fire acupuncture combined with western medicine to improve acute herpes zoster neuralgia

Randomized controlled trial of fire acupuncture combined with western medicine to improve acute herpes zoster neuralgia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006703
Enrollment
Unknown
Registered
2022-10-13
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Herpes Zoster

Interventions

Ordinary acupuncture group:Basic drugs + Ordinary acupuncture
Basic Group:Basic drugs
Fire needle group:Basic drugs + Fire needle

Sponsors

The First Affiliated Hospital of Anhui University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the above-mentioned Western and Chinese medical diagnostic criteria for herpes zoster;? ? (2) Age between 18 and 75, no gender limitation;? ? (3) Patients with herpes and pain occurring within 1-7 days without receiving antiviral, analgesic, nerve nutrition, acupuncture and other traditional Chinese and Western medicine treatment;? ? (4) Those who have signed the informed consent to understand and accept the treatment plan in this study.

Exclusion criteria

Exclusion criteria: (1) Patients with herpes zoster without rash, herpes zoster with stenting, herpes zoster with disseminated, herpes zoster with eye, herpes zoster with ear, herpes zoster with meninges, herpes zoster with bullosa, hemorrhagic, gangrene and so on;? (2) Those who have received corticosteroid or immunosuppressive therapy in the past 1 month;? ? (3) Pregnant or lactating women;? ? (4) People with allergic constitution and allergic to a variety of drugs;? ? (5) scar body;? ? (6) Patients suffering from serious cardiovascular and cerebrovascular diseases, liver, kidney, hematopoietic system and other primary diseases or systemic organ function failure, diabetes, hemophilia, malignant tumor, mental illness, and patients with abnormal coagulation function; (7) Patients in critical condition who are difficult to evaluate the treatment effect.

Design outcomes

Primary

MeasureTime frame
VAS Pain Scale;

Secondary

MeasureTime frame
PSQI;HAMD;Incidence of neuralgia;SF-36;HAMA;

Countries

Chinese

Contacts

Public ContactYuan Aihong
490603279@qq.com15395001068

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026